FDA approval of nivolumab and ipilimumab for hepatocellular carcinoma

Opdivo Yervoy

On March 10th 2020 The U.S. Food and Drug Administration (FDA) approved a combination of Bristol-Myers Squibb‘s immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of hepatocellular carcinoma (HCC) patients who received prior treatment with Nexavar (sorafenib), the company said.

Approval based on CheckMate -040 trial (NCT01658878) in which Opdivo + Yervoy showed an overall response rate of 33% (16/49; 95% CI: 20-48) in this patient population.

The therapy features a potentially synergistic mechanism of action that targets two different checkpoints (PD-1 and CTLA-4) and works in complementary ways

Keywords: Yervoy, nivolumab, Opdivo, ipilimumab.

Leave a Reply

Your email address will not be published. Required fields are marked *